Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications

•CYP2J2 synthesizes epoxylipids that act as potent signaling mediators•A role for these lipids has been suggested for pain, angiogenesis and tumor growth•Several CYP2J2-inhibitors have been identified – among them already approved drugs•Inhibiting CYP2J2 may introduce novel therapeutic options for p...

Full description

Saved in:
Bibliographic Details
Published in:Drug discovery today 2020-09, Vol.25 (9), p.1744-1753
Main Authors: Sisignano, Marco, Steinhilber, Dieter, Parnham, Michael J., Geisslinger, Gerd
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c428t-20dcafdaa5e569a0d2b121a3b7f0877065245713105a6d78cdc1c599b4f0c7263
cites cdi_FETCH-LOGICAL-c428t-20dcafdaa5e569a0d2b121a3b7f0877065245713105a6d78cdc1c599b4f0c7263
container_end_page 1753
container_issue 9
container_start_page 1744
container_title Drug discovery today
container_volume 25
creator Sisignano, Marco
Steinhilber, Dieter
Parnham, Michael J.
Geisslinger, Gerd
description •CYP2J2 synthesizes epoxylipids that act as potent signaling mediators•A role for these lipids has been suggested for pain, angiogenesis and tumor growth•Several CYP2J2-inhibitors have been identified – among them already approved drugs•Inhibiting CYP2J2 may introduce novel therapeutic options for pain and tumor growth In contrast to other drug-metabolizing cytochrome P450 (CYP) oxygenases, CYP2J2 shows considerable extrahepatic activity and is responsible for the olefin epoxidation of several polyunsaturated fatty acid (PUFA) precursors. The resulting epoxylipids act as signaling mediators and show a remarkable variety of biological functions. Recent studies suggest a role of selected CYP2J2-derived epoxylipids and their metabolites in chronic pain, as well as angiogenesis, hematopoiesis, metabolic disorders, and tumor growth. These pleiotropic effects of CYP products imply that targeting CYP2J2 could represent a novel therapeutic strategy in these fields. Here, we explore the biological functions of CYP2J2-derived epoxylipids and discuss therapeutic implications of the CYP2J2 inhibitors that are known so far.
doi_str_mv 10.1016/j.drudis.2020.07.002
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2423056508</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1359644620302610</els_id><sourcerecordid>2423056508</sourcerecordid><originalsourceid>FETCH-LOGICAL-c428t-20dcafdaa5e569a0d2b121a3b7f0877065245713105a6d78cdc1c599b4f0c7263</originalsourceid><addsrcrecordid>eNp9kDtPxDAQhC0E4v0PEEpJQcLaie2EAgmdjpeQoICCynJsB_aUS4KdIPj3-HRASbVTzOzsfoQcUcgoUHG2yKyfLIaMAYMMZAbANsguLWWZ8jJnm1HnvEpFUYgdshfCAoCyiottspMzwVlO6S65m38Obe-xe01mL4_sjp0nLQ5ok6WzqMfeh9MEuzescaUT3dlkfHNeD24a0SS4HFo0esS-Cwdkq9FtcIc_c588X82fZjfp_cP17ezyPjUFK8eUgTW6sVpzx0WlwbKaMqrzWjZQSgnxsoJLmlPgWlhZGmuo4VVVFw0YyUS-T07Wewffv08ujGqJwbi21Z3rp6BYwXLggkMZrcXaanwfgneNGjwutf9SFNSKolqoNUW1oqhAqkgxxo5_GqY6cvgL_WKLhou1wcU_P9B5FQy6zkRm3plR2R7_b_gGCreEgA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2423056508</pqid></control><display><type>article</type><title>Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications</title><source>ScienceDirect Freedom Collection</source><creator>Sisignano, Marco ; Steinhilber, Dieter ; Parnham, Michael J. ; Geisslinger, Gerd</creator><creatorcontrib>Sisignano, Marco ; Steinhilber, Dieter ; Parnham, Michael J. ; Geisslinger, Gerd</creatorcontrib><description>•CYP2J2 synthesizes epoxylipids that act as potent signaling mediators•A role for these lipids has been suggested for pain, angiogenesis and tumor growth•Several CYP2J2-inhibitors have been identified – among them already approved drugs•Inhibiting CYP2J2 may introduce novel therapeutic options for pain and tumor growth In contrast to other drug-metabolizing cytochrome P450 (CYP) oxygenases, CYP2J2 shows considerable extrahepatic activity and is responsible for the olefin epoxidation of several polyunsaturated fatty acid (PUFA) precursors. The resulting epoxylipids act as signaling mediators and show a remarkable variety of biological functions. Recent studies suggest a role of selected CYP2J2-derived epoxylipids and their metabolites in chronic pain, as well as angiogenesis, hematopoiesis, metabolic disorders, and tumor growth. These pleiotropic effects of CYP products imply that targeting CYP2J2 could represent a novel therapeutic strategy in these fields. Here, we explore the biological functions of CYP2J2-derived epoxylipids and discuss therapeutic implications of the CYP2J2 inhibitors that are known so far.</description><identifier>ISSN: 1359-6446</identifier><identifier>EISSN: 1878-5832</identifier><identifier>DOI: 10.1016/j.drudis.2020.07.002</identifier><identifier>PMID: 32652311</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><ispartof>Drug discovery today, 2020-09, Vol.25 (9), p.1744-1753</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c428t-20dcafdaa5e569a0d2b121a3b7f0877065245713105a6d78cdc1c599b4f0c7263</citedby><cites>FETCH-LOGICAL-c428t-20dcafdaa5e569a0d2b121a3b7f0877065245713105a6d78cdc1c599b4f0c7263</cites><orcidid>0000-0002-7098-8451 ; 0000-0002-7581-0951</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32652311$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sisignano, Marco</creatorcontrib><creatorcontrib>Steinhilber, Dieter</creatorcontrib><creatorcontrib>Parnham, Michael J.</creatorcontrib><creatorcontrib>Geisslinger, Gerd</creatorcontrib><title>Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>•CYP2J2 synthesizes epoxylipids that act as potent signaling mediators•A role for these lipids has been suggested for pain, angiogenesis and tumor growth•Several CYP2J2-inhibitors have been identified – among them already approved drugs•Inhibiting CYP2J2 may introduce novel therapeutic options for pain and tumor growth In contrast to other drug-metabolizing cytochrome P450 (CYP) oxygenases, CYP2J2 shows considerable extrahepatic activity and is responsible for the olefin epoxidation of several polyunsaturated fatty acid (PUFA) precursors. The resulting epoxylipids act as signaling mediators and show a remarkable variety of biological functions. Recent studies suggest a role of selected CYP2J2-derived epoxylipids and their metabolites in chronic pain, as well as angiogenesis, hematopoiesis, metabolic disorders, and tumor growth. These pleiotropic effects of CYP products imply that targeting CYP2J2 could represent a novel therapeutic strategy in these fields. Here, we explore the biological functions of CYP2J2-derived epoxylipids and discuss therapeutic implications of the CYP2J2 inhibitors that are known so far.</description><issn>1359-6446</issn><issn>1878-5832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kDtPxDAQhC0E4v0PEEpJQcLaie2EAgmdjpeQoICCynJsB_aUS4KdIPj3-HRASbVTzOzsfoQcUcgoUHG2yKyfLIaMAYMMZAbANsguLWWZ8jJnm1HnvEpFUYgdshfCAoCyiottspMzwVlO6S65m38Obe-xe01mL4_sjp0nLQ5ok6WzqMfeh9MEuzescaUT3dlkfHNeD24a0SS4HFo0esS-Cwdkq9FtcIc_c588X82fZjfp_cP17ezyPjUFK8eUgTW6sVpzx0WlwbKaMqrzWjZQSgnxsoJLmlPgWlhZGmuo4VVVFw0YyUS-T07Wewffv08ujGqJwbi21Z3rp6BYwXLggkMZrcXaanwfgneNGjwutf9SFNSKolqoNUW1oqhAqkgxxo5_GqY6cvgL_WKLhou1wcU_P9B5FQy6zkRm3plR2R7_b_gGCreEgA</recordid><startdate>202009</startdate><enddate>202009</enddate><creator>Sisignano, Marco</creator><creator>Steinhilber, Dieter</creator><creator>Parnham, Michael J.</creator><creator>Geisslinger, Gerd</creator><general>Elsevier Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7098-8451</orcidid><orcidid>https://orcid.org/0000-0002-7581-0951</orcidid></search><sort><creationdate>202009</creationdate><title>Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications</title><author>Sisignano, Marco ; Steinhilber, Dieter ; Parnham, Michael J. ; Geisslinger, Gerd</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c428t-20dcafdaa5e569a0d2b121a3b7f0877065245713105a6d78cdc1c599b4f0c7263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sisignano, Marco</creatorcontrib><creatorcontrib>Steinhilber, Dieter</creatorcontrib><creatorcontrib>Parnham, Michael J.</creatorcontrib><creatorcontrib>Geisslinger, Gerd</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sisignano, Marco</au><au>Steinhilber, Dieter</au><au>Parnham, Michael J.</au><au>Geisslinger, Gerd</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2020-09</date><risdate>2020</risdate><volume>25</volume><issue>9</issue><spage>1744</spage><epage>1753</epage><pages>1744-1753</pages><issn>1359-6446</issn><eissn>1878-5832</eissn><abstract>•CYP2J2 synthesizes epoxylipids that act as potent signaling mediators•A role for these lipids has been suggested for pain, angiogenesis and tumor growth•Several CYP2J2-inhibitors have been identified – among them already approved drugs•Inhibiting CYP2J2 may introduce novel therapeutic options for pain and tumor growth In contrast to other drug-metabolizing cytochrome P450 (CYP) oxygenases, CYP2J2 shows considerable extrahepatic activity and is responsible for the olefin epoxidation of several polyunsaturated fatty acid (PUFA) precursors. The resulting epoxylipids act as signaling mediators and show a remarkable variety of biological functions. Recent studies suggest a role of selected CYP2J2-derived epoxylipids and their metabolites in chronic pain, as well as angiogenesis, hematopoiesis, metabolic disorders, and tumor growth. These pleiotropic effects of CYP products imply that targeting CYP2J2 could represent a novel therapeutic strategy in these fields. Here, we explore the biological functions of CYP2J2-derived epoxylipids and discuss therapeutic implications of the CYP2J2 inhibitors that are known so far.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>32652311</pmid><doi>10.1016/j.drudis.2020.07.002</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0002-7098-8451</orcidid><orcidid>https://orcid.org/0000-0002-7581-0951</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1359-6446
ispartof Drug discovery today, 2020-09, Vol.25 (9), p.1744-1753
issn 1359-6446
1878-5832
language eng
recordid cdi_proquest_miscellaneous_2423056508
source ScienceDirect Freedom Collection
title Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T07%3A02%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Exploring%20CYP2J2:%20lipid%20mediators,%20inhibitors%20and%20therapeutic%20implications&rft.jtitle=Drug%20discovery%20today&rft.au=Sisignano,%20Marco&rft.date=2020-09&rft.volume=25&rft.issue=9&rft.spage=1744&rft.epage=1753&rft.pages=1744-1753&rft.issn=1359-6446&rft.eissn=1878-5832&rft_id=info:doi/10.1016/j.drudis.2020.07.002&rft_dat=%3Cproquest_cross%3E2423056508%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c428t-20dcafdaa5e569a0d2b121a3b7f0877065245713105a6d78cdc1c599b4f0c7263%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2423056508&rft_id=info:pmid/32652311&rfr_iscdi=true